The DOI matches its Crossref record; 290 of the 290 references it cites were found in a registry or an index.
Gender differences in the effects of cardiovascular drugs
Open accessAbstract
Although sex-specific differences in cardiovascular medicine are well known, the exact influences of sex on the effect of cardiovascular drugs remain unclear. Women and men differ in body composition and physiology (hormonal influences during the menstrual cycle, menopause, and pregnancy) and they present differences in drug pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics, so that is not rare that they may respond differently to cardiovascular drugs. Furthermore, women are also less often treated with evidence-based drugs thereby preventing optimization of therapeutics for women of all ages, experience more relevant adverse drug reactions than men, and remain underrepresented in most clinical trials. Thus, current guidelines for prevention, diagnosis, and medical treatment for cardiovascular diseases are based on trials conducted predominantly in middle-aged men. A better understanding of these sex-related differences is fundamental to improve the safety and efficacy of cardiovascular drugs and for developing proper individualized cardiovascular therapeutic strategies both in men and women. This review briefly summarizes gender differences in the pharmacokinetics and pharmacodynamics of cardiovascular drugs and provides recommendations to close the gaps in our understanding of sex-specific differences in drug efficacy and safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Self-citationTicagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Self-citationPfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Heart Disease and Stroke Statistics—2015 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., de Ferranti, S., Després, J.-P., Fullerton, H. J., Howard, V. J., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000152 · Cited by 5,797
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309023291001 · Cited by 4,055
Swedberg, K., & Kjekshus, J. (1988) · The American Journal of Cardiology · doi:10.1016/s0002-9149(88)80087-0 · Cited by 3,762
(1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271003 · Cited by 3,725
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The Protective Effects of Estrogen on the Cardiovascular System
Mendelsohn, M. E., & Karas, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906103402306 · Cited by 3,103
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Dienstl, F., Backer, G. D., Cairns, J., Pedersen, F., Kala, R., Boissel, J., Schroeder, R., Horgan, J., & Tognoni, G. (1988) · The Lancet · Cited by 2,754
Fibrinolytic Therapy Trialists' (FTT) Collaborative Group (1994) · The Lancet · doi:10.1016/s0140-6736(94)91161-4 · Cited by 2,744
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Swedberg, K., Komajda, M., Böhm, M., Borer, J. S., Ford, I., Dubost-Brama, A., Lerebours, G., & Tavazzi, L. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61198-1 · Cited by 2,563 · cited 1×
“HF, LV systolic dysfunction (LVEF <_ 35%), and heart rate >_ 70 bpm.(192)”
BackgroundJulius, S., Kjeldsen, S. E., Weber, M., Brunner, H. R., Ekman, S., Hansson, L., Hua, T., Laragh, J., McInnes, G. T., Mitchell, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16451-9 · Cited by 2,558
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471
EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION
GRUPPOITALIANOPERLOSTUDIODELL (1986) · The Lancet · doi:10.1016/s0140-6736(86)92368-8 · Cited by 2,440
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Julian, D. G., Moss, A. J., Murray, G. D., Poole-Wilson, P. A., Simoons, M. L., Ball, S., Bender, N., Cleland, J. G. F., Dl, C., Pj, C., et al. (1993) · PubMed · Cited by 2,144
Mosca, L., Benjamin, E. J., Berra, K., Bezanson, J. L., Dolor, R. J., Lloyd-Jones, D. M., Newby, L. K., Piña, I. L., Roger, V. L., Shaw, L. J., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820faaf8 · Cited by 2,143
(1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420130036007 · Cited by 2,071
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
The Effect of Race and Sex on Physicians' Recommendations for Cardiac Catheterization
Schulman, K. A., Berlin, J. A., Harless, W., Kerner, J. F., Sistrunk, S., Gersh, B. J., Dubé, R., Taleghani, C. K., Burke, J. E., Williams, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902253400806 · Cited by 1,934
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J.-P., Bhatt, D. L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K. A. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112277 · Cited by 1,897
Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., Östergren, J., & Yusuf, S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14282-1 · Cited by 1,889
Julian, D. G., Moss, A. J., Murray, G. D., Poole-Wilson, P. A., Simoons, M. L., Ball, S., Bender, N., Cleland, J. G. F., Dl, C., Pj, C., et al. (1993) · The Lancet · Cited by 1,860
Policy: NIH to balance sex in cell and animal studies
Clayton, J. A., & Collins, F. S. (2014) · Nature · doi:10.1038/509282a · Cited by 1,816 · cited 1×
“might contribute to the lack of reproducibility of biomedical research.(312) Thus, gender-based analyses are essential to elucidate possible differences in cardiovascular drug efficacy and safety.”
BackgroundGarg, R. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520420066040 · Cited by 1,771
Pitt, B., Segal, R., Martinez, F. A., Meurers, G., Cowley, A. J., Thomas, I., Deedwania, P. C., Ney, D. E., Snavely, D. B., & Chang, P. I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01187-2 · Cited by 1,665
Flather, M. D., Yusuf, S., Køber, L., Pfeffer, M., Hall, A., Murray, G., Torp-Pedersen, C., Ball, S., Pogue, J., Moyé, L., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02212-1 · Cited by 1,585
Self-citationStroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Packer, M., Fowler, M. B., Roecker, E. B., Coats, A. J. S., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Staiger, C., et al. (2002) · Circulation · doi:10.1161/01.cir.0000035653.72855.bf · Cited by 1,364
Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa055443 · Cited by 1,228
Low-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,218
Dickstein, K., & Kjekshus, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09895-1 · Cited by 1,203
Sex Differences in Pharmacokinetics and Pharmacodynamics
Soldin, O. P., & Mattison, D. R. (2009) · Clinical Pharmacokinetics · doi:10.2165/00003088-200948030-00001 · Cited by 1,163 · cited 2×
“However, transdermal absorption is similar in both sexes.(12,15,29)”
BackgroundLincoff, A. M., Bittl, J. A., Harrington, R. A., Feit, F., Kleiman, N. S., Jackman, J. D., Sarembock, I. J., Cohen, D. J., Spriggs, D., Ebrahimi, R., et al. (2003) · JAMA · doi:10.1001/jama.289.7.853 · Cited by 1,162
TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION
Wilcox, R. G., Olsson, C. G., Skene, A. M., Von Der Lippe, G., Jensen, G., Hampton, J. R., & For The Asset Study Group (1988) · The Lancet · doi:10.1016/s0140-6736(88)92656-6 · Cited by 1,153
Wing, L. M. H., Reid, C. M., Ryan, P., Beilin, L. J., Brown, M. A., Jennings, G. L. R., Johnston, C. I., McNeil, J. J., Macdonald, G. J., Marley, J. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021716 · Cited by 1,130
Fox, K., Ford, I., Steg, P. G., Tendera, M., & Ferrari, R. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61170-8 · Cited by 1,099
Lee, K. L., Woodlief, L. H., Topol, E. J., Weaver, W. D., Betriu, A., Col, J., Simoons, M., Aylward, P., Van de Werf, F., & Califf, R. M. (1995) · Circulation · doi:10.1161/01.cir.91.6.1659 · Cited by 1,093
Cardiovascular Disease in Women: Clinical Perspectives
Garcia, M., Mulvagh, S. L., Bairey Merz, C. N., Buring, J. E., & Manson, J. E. (2016) · Circulation Research · doi:10.1161/circresaha.116.307547 · Cited by 1,080
Van Spall, H. G. C., Toren, A., Kiss, A., & Fowler, R. A. (2007) · JAMA · doi:10.1001/jama.297.11.1233 · Cited by 1,055
Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction
Torp-Pedersen, C., Møller, M., Bloch-Thomsen, P. E., Køber, L., Sandøe, E., Egstrup, K., Agner, E., Carlsen, J., Videbæk, J., Marchant, B., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411201 · Cited by 1,012
Self-citationBoersma, E., Harrington, R. A., Moliterno, D. J., White, H., Théroux, P., Van de Werf, F., de Torbal, A., Armstrong, P. W., Wallentin, L. C., Wilcox, R. G., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07442-1 · Cited by 991
Female Gender as a Risk Factor for Torsades de Pointes Associated With Cardiovascular Drugs
Makkar, R. R. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510210076031 · Cited by 971
Drug induced QT prolongation and torsades de pointes
Yap, Y. G., & Camm, A. J. (2003) · Heart · doi:10.1136/heart.89.11.1363 · Cited by 958
Moscucci, M. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00485-8 · Cited by 918
The OASIS-6 Trial Group* (2006) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.295.13.joc60038 · Cited by 906
Profile and prevalence of aspirin resistance in patients with cardiovascular disease
Gum, P. A., Kottke-Marchant, K., Poggio, E. D., Gurm, H., Welsh, P. A., Brooks, L., Sapp, S. K., & Topol, E. J. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01631-9 · Cited by 820
Manoukian, S. V., Feit, F., Mehran, R., Voeltz, M. D., Ebrahimi, R., Hamon, M., Dangas, G. D., Lincoff, A. M., White, H. D., Moses, J. W., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.027 · Cited by 798
Brugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792
Berger, J. S., Roncaglioni, M. C., Avanzini, F., Pangrazzi, I., Tognoni, G., & Brown, D. L. (2006) · JAMA · doi:10.1001/jama.295.3.306 · Cited by 789
Variability in platelet responsiveness to clopidogrel among 544 individuals
Serebruany, V. L., Steinhubl, S. R., Berger, P. B., Malinin, A. I., Bhatt, D. L., & Topol, E. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.09.067 · Cited by 777
Association of Serum Digoxin Concentration and Outcomes in Patients With Heart Failure
Rathore, S. S., Curtis, J. P., Wang, Y., Bristow, M. R., & Krumholz, H. M. (2003) · JAMA · doi:10.1001/jama.289.7.871 · Cited by 772
Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes
(2016) · European Heart Journal · doi:10.1093/eurheartj/ehv598 · Cited by 739
Statin-Associated Side Effects
Thompson, P. D., Panza, G., Zaleski, A., & Taylor, B. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.071 · Cited by 739
Sirtori, C. R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.03.002 · Cited by 691
Sex-Based Differences in the Effect of Digoxin for the Treatment of Heart Failure
Rathore, S. S., Wang, Y., & Krumholz, H. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021266 · Cited by 690
Low-molecular-weight heparin during instability in coronary artery disease
Fragmin during Instability in Coronary Artery Disease (FRISC) study group (1996) · The Lancet · doi:10.1016/s0140-6736(96)91270-2 · Cited by 685
Alexander, K. P. (2005) · JAMA · doi:10.1001/jama.294.24.3108 · Cited by 677
Stangier, J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00001 · Cited by 655
Blomkalns, A. L., Chen, A. Y., Hochman, J. S., Peterson, E. D., Trynosky, K., Diercks, D. B., Brogan, G. X., Boden, W. E., Roe, M. T., Ohman, E. M., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.11.055 · Cited by 653
Sex differences in the evolution of the electrocardiographic QT interval with age.
Rautaharju, P. M., Sh, Z., Wong, S., Hp, C., Berenson, G. S., Prineas, R., & Davignon, A. (1992) · PubMed · Cited by 635
The Role of the Funny Current in Pacemaker Activity
DiFrancesco, D. (2010) · Circulation Research · doi:10.1161/circresaha.109.208041 · Cited by 587
Tardif, J.-C., Ford, I., Tendera, M., Bourassa, M. G., & Fox, K. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi586 · Cited by 582
Cardiovascular disease in Europe — epidemiological update 2015
Townsend, N., Nichols, M., Scarborough, P., & Rayner, M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv428 · Cited by 568
Sex Differences in Pharmacokinetics and Pharmacodynamics
Gandhi, M., Aweeka, F., Greenblatt, R. M., & Blaschke, T. F. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121453 · Cited by 542
Bleeding complications in oral anticoagulant therapy. An analysis of risk factors
van der Meer, F. J. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.153.13.1557 · Cited by 538
Hart, R. G., Pearce, L. A., McBride, R., Rothbart, R. M., & Asinger, R. W. (1999) · Stroke · doi:10.1161/01.str.30.6.1223 · Cited by 533
The Exclusion of the Elderly and Women From Clinical Trials in Acute Myocardial Infarction
Gurwitz, J. H. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490110055029 · Cited by 532
Sex Is A Major Determinant of Cyp3a4 Expression in Human Liver
Wolbold, R., Klein, K., Burk, O., Nüssler, A. K., Neuhaus, P., Eichelbaum, M., Schwab, M., & Zanger, U. M. (2003) · Hepatology · doi:10.1002/hep.1840380424 · Cited by 529
Jb, B., & Gj, R. (1964) · PubMed · Cited by 508
Gender Effects in Pharmacokinetics and Pharmacodynamics
Harris, R. Z., Benet, L. Z., & Schwartz, J. B. (1995) · Drugs · doi:10.2165/00003495-199550020-00003 · Cited by 506
Shekelle, P. G., Rich, M. W., Morton, S. C., Atkinson, C. S. W., Tu, W., Maglione, M., Rhodes, S., Barrett, M., Fonarow, G. C., Greenberg, B., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00262-6 · Cited by 492 · cited 3×
“Hypertensive men are treated more frequently with renin-angiotensin-aldosterone system inhibitors (RAASIs), while diuretics are more frequently prescribed in women.209 The lower use of RAASIs in young women may be related to their potential teratogenic effects.210–212 However, this lower use persists in women in all a…”
BackgroundInfluentialA comprehensive view of sex-specific issues related to cardiovascular disease
Pilote, L., Dasgupta, K., Guru, V., Humphries, K. H., McGrath, J., Norris, C., Rabi, D., Tremblay, J., Alamian, A., Barnett, T., et al. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.051455 · Cited by 476
Caulin-Glaser, T., García-Cardeña, G., Sarrel, P., Sessa, W. C., & Bender, J. R. (1997) · Circulation Research · doi:10.1161/01.res.81.5.885 · Cited by 473
Fang, M. C., Singer, D. E., Chang, Y., Hylek, E. M., Henault, L. E., Jensvold, N. G., & Go, A. S. (2005) · Circulation · doi:10.1161/circulationaha.105.553438 · Cited by 469
The Influence of Sex on Pharmacokinetics
Schwartz, J. B. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342020-00001 · Cited by 467
Sex Difference in Risk of Torsade de Pointes With d,l- Sotalol
Lehmann, M. H., Hardy, S., Archibald, D., Quart, B., & MacNeil, D. J. (1996) · Circulation · doi:10.1161/01.cir.94.10.2535 · Cited by 458
How Important Are Gender Differences in Pharmacokinetics?
Meibohm, B., Beierle, I., & Derendorf, H. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00002 · Cited by 454
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative
Culver, A. L. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.625 · Cited by 444
Kannankeril, P., Roden, D. M., & Darbar, D. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003723 · Cited by 440
Bleeding Complications in Oral Anticoagulant Therapy: An Analysis of Risk Factors
van der Meer, F. J. M. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410130073007 · Cited by 433
Do Women Have More Adverse Drug Reactions?
Rademaker, M. (2001) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200102060-00001 · Cited by 432
Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
Mills, E. J., Rachlis, B., Wu, P., Devereaux, P. J., Arora, P., & Perri, D. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.039 · Cited by 423
Manteuffel, M., Williams, S., Chen, W., Verbrugge, R. R., Pittman, D. G., & Steinkellner, A. (2014) · Journal of Women's Health · doi:10.1089/jwh.2012.3972 · Cited by 402
Lincoff, A. M. (2004) · JAMA · doi:10.1001/jama.292.6.696 · Cited by 401
Steg, P. G., Huber, K., Andreotti, F., Arnesen, H., Atar, D., Badimon, L., Bassand, J.-P., De Caterina, R., Eikelboom, J. A., Gulba, D., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr204 · Cited by 395
Self-citationStramba-Badiale, M., Fox, K. M., Priori, S. G., Collins, P., Daly, C., Graham, I., Jonsson, B., Schenck-Gustafsson, K., & Tendera, M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi819 · Cited by 392
Renin angiotensin system and gender differences in the cardiovascular system
Fischer, M. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00479-5 · Cited by 384
Geller, S. E., Koch, A., Pellettieri, B., & Carnes, M. (2011) · Journal of Women's Health · doi:10.1089/jwh.2010.2469 · Cited by 374
Swan, S. K., & Hursting, M. J. (2000) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.4.318.34881 · Cited by 368
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Langslet, G., Bays, H., Blom, D., Eriksson, M., Dent, R., Wasserman, S. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.006 · Cited by 361
Thavendiranathan, P. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.21.2307 · Cited by 351
Sex Differences in Drug Disposition
Soldin, O. P., Chung, S. H., & Mattison, D. R. (2011) · BioMed Research International · doi:10.1155/2011/187103 · Cited by 341
Sex Differences in Platelet Reactivity and Response to Low-Dose Aspirin Therapy
Becker, D. M., Segal, J., Vaidya, D., Yanek, L. R., Herrera-Galeano, J. E., Bray, P. F., Moy, T. F., Becker, L. C., & Faraday, N. (2006) · JAMA · doi:10.1001/jama.295.12.1420 · Cited by 332
Anderson, G. D. (2005) · Journal of Women's Health · doi:10.1089/jwh.2005.14.19 · Cited by 321
Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension
Israili, Z. (2000) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000991 · Cited by 318
Drug-Induced QT Prolongation in Women During the Menstrual Cycle
Rodriguez, I. (2001) · JAMA · doi:10.1001/jama.285.10.1322 · Cited by 311
Testosterone Increases Human Platelet Thromboxane A2Receptor Density and Aggregation Responses
Ajayi, A. A. L., Mathur, R., & Halushka, P. V. (1995) · Circulation · doi:10.1161/01.cir.91.11.2742 · Cited by 306
Cheung, B. M. Y., Lauder, I. J., Lau, C., & Kumana, C. R. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02060.x · Cited by 304
Maas, A. H. E. M., van der Schouw, Y. T., Regitz-Zagrosek, V., Swahn, E., Appelman, Y. E., Pasterkamp, G., ten Cate, H., Nilsson, P. M., Huisman, M. V., Stam, H. C. G., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr048 · Cited by 294
The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates
Cotreau, M. M., von Moltke, L. L., & Greenblatt, D. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00002 · Cited by 292
Gender differences in advanced heart failure: insights from the BEST study
Ghali, J. K., Krause-Steinrauf, H. J., Adams, K. F., Khan, S. S., Rosenberg, Y. D., Yancy, C. W., Young, J. B., Goldman, S., Peberdy, M. A., & Lindenfeld, J. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.05.012 · Cited by 292
Gender and the renin–angiotensin–aldosterone system
Komukai, K., Mochizuki, S., & Yoshimura, M. (2010) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2010.00854.x · Cited by 291
Therapeutic implications of the gender-specific aspects of cardiovascular disease
Regitz-Zagrosek, V. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2032 · Cited by 284
Adams, K. F., Patterson, J. H., Gattis, W. A., O’Connor, C. M., Lee, C. R., Schwartz, T. A., & Gheorghiade, M. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.091 · Cited by 283
Granger, C. B., Hirsh, J., Califf, R. M., Col, J., White, H. D., Betriu, A., Woodlief, L. H., Lee, K. L., Bovill, E. G., Simes, R. J., et al. (1996) · Circulation · doi:10.1161/01.cir.93.5.870 · Cited by 281
Sex and age differences in human platelet aggregation
JOHNSON, M., RAMEY, E., & RAMWELL, P. W. (1975) · Nature · doi:10.1038/253355a0 · Cited by 274
Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases
Jochmann, N., Stangl, K., Garbe, E., Baumann, G., & Stangl, V. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi397 · Cited by 272
Alexander, K. P., Chen, A. Y., Newby, L. K., Schwartz, J. B., Redberg, R. F., Hochman, J. S., Roe, M. T., Gibler, W. B., Ohman, E. M., & Peterson, E. D. (2006) · Circulation · doi:10.1161/circulationaha.106.620815 · Cited by 260
Baumhäkel, M., Müller, U., & Böhm, M. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfn041 · Cited by 258
Weaver, W. D. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530340041027 · Cited by 257
The Current State of Knowledge on Age, Sex, and Their Interactions on Clinical Pharmacology
Schwartz, J. B. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100226 · Cited by 256
Berkowitz, S. D., Granger, C. B., Pieper, K. S., Lee, K. L., Gore, J. M., Simoons, M., Armstrong, P. W., Topol, E. J., & Califf, R. M. (1997) · Circulation · doi:10.1161/01.cir.95.11.2508 · Cited by 256
Franconi, F., & Campesi, I. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12362 · Cited by 251
Meta-Analysis of Statin Effects in Women Versus Men
Kostis, W. J., Cheng, J. Q., Dobrzynski, J. M., Cabrera, J., & Kostis, J. B. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.09.067 · Cited by 247
Warfarin Maintenance Dosing Patterns in Clinical Practice
Garcia, D., Regan, S., Crowther, M., Hughes, R. A., & Hylek, E. M. (2005) · Chest · doi:10.1378/chest.127.6.2049 · Cited by 241
Kent, D. M., Price, L. L., Ringleb, P., Hill, M. D., & Selker, H. P. (2005) · Stroke · doi:10.1161/01.str.0000150515.15576.29 · Cited by 239
Long-Term Safety and Efficacy of Drug-Eluting versus Bare-Metal Stents in Sweden
James, S. K., Stenestrand, U., Lindbäck, J., Carlsson, J., Scherstén, F., Nilsson, T., Wallentin, L., & Lagerqvist, B. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809902 · Cited by 237
Gurwitz, J. H., Gore, J. M., Goldberg, R. J., Barron, H. V., Breen, T., Rundle, A. C., Sloan, M. A., French, W., & Rogers, W. J. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-8-199810150-00002 · Cited by 233
Ghali, J. K., Piña, I. L., Gottlieb, S. S., Deedwania, P. C., & Wikstrand, J. C. (2002) · Circulation · doi:10.1161/01.cir.0000012546.20194.33 · Cited by 231
Is Gender a Risk Factor for Adverse Drug Reactions?: The Example of Drug-Induced Long QT Syndrome
Drici, M.-D., & Cl??ment, N. (2001) · Drug Safety · doi:10.2165/00002018-200124080-00002 · Cited by 226
Berg, U. B. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl227 · Cited by 223
Efficacy and Toxicity of Heparin in Relation to Age and Sex
Jick, H., Slone, D., Borda, I. T., & Shapiro, S. (1968) · New England Journal of Medicine · doi:10.1056/nejm196808082790603 · Cited by 220
Martin, R. M., Biswas, P. N., Freemantle, S. N., Pearce, G. L., & Mann, R. D. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00817.x · Cited by 219
Sullivan, J. C. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00864.2007 · Cited by 212
Beyond Unfractionated Heparin and Warfarin: Current and Future Advances
Hirsh, J., O’Donnell, M., & Eikelboom, J. W. (2007) · Circulation · doi:10.1161/circulationaha.106.685974 · Cited by 211
Gender Difference in the Cycle Length-Dependent QT and Potassium Currents in Rabbits
Liu, X.-K., Katchman, A., Drici, M.-D., Ebert, S. N., Ducic, I., Morad, M., & Woosley, R. L. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37435-x · Cited by 209
Gastrointestinal Transit and Drug Absorption
Kimura, T., & Higaki, K. (2002) · Biological & Pharmaceutical Bulletin · doi:10.1248/bpb.25.149 · Cited by 205
Pancholy, S. B., Sharma, P. S., Pancholy, D. S., Patel, T. M., Callans, D. J., & Marchlinski, F. E. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.10.035 · Cited by 204
Aggregometry detects platelet hyperreactivity in healthy individuals
Yee, D. L., Sun, C. W., Bergeron, A. L., Dong, J.-F., & Bray, P. F. (2005) · Blood · doi:10.1182/blood-2005-03-1290 · Cited by 203
Women encounter ADRs more often than do men
Zopf, Y., Rabe, C., Neubert, A., Gaßmann, K. G., Rascher, W., Hahn, E. G., Brune, K., & Dormann, H. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0494-6 · Cited by 200
Bock, K. W., Schrenk, D., Forster, A., Griese, E.-U., M??rike, K., Brockmeier, D., & Eichelbaum, M. (1994) · Pharmacogenetics · doi:10.1097/00008571-199408000-00005 · Cited by 199
Gaborit, N., Varro, A., Le Bouter, S., Szuts, V., Escande, D., Nattel, S., & Demolombe, S. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.06.005 · Cited by 194
Ruzyllo, W., Tendera, M., Ford, I., & Fox, K. M. (2007) · Drugs · doi:10.2165/00003495-200767030-00005 · Cited by 192
Warfarin therapy: evolving strategies in anticoagulation.
Horton, J. D., & Bushwick, B. M. (1999) · PubMed · Cited by 190
Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery
Freire, A. C., Basit, A. W., Choudhary, R., Piong, C. W., & Merchant, H. A. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.04.069 · Cited by 190
Factors influencing underutilization of evidence-based therapies in women
Bugiardini, R., Yan, A. T., Yan, R. T., Fitchett, D., Langer, A., Manfrini, O., Goodman, S. G., & on behalf of the Canadian Acute Coronary Syndrome Registry I and II Investigators (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr027 · Cited by 190
Hochholzer, W., Wiviott, S. D., Antman, E. M., Contant, C. F., Guo, J., Giugliano, R. P., Dalby, A. J., Montalescot, G., & Braunwald, E. (2011) · Circulation · doi:10.1161/circulationaha.110.002683 · Cited by 183
Gender Disparities in Evidence-Based Statin Therapy in Patients With Cardiovascular Disease
Virani, S. S., Woodard, L. D., Ramsey, D. J., Urech, T. H., Akeroyd, J. M., Shah, T., Deswal, A., Bozkurt, B., Ballantyne, C. M., & Petersen, L. A. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.09.041 · Cited by 182
Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update
Teng, R. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0290-2 · Cited by 177
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.115 · Cited by 175
Rosano, G. M. C., Lewis, B., Agewall, S., Wassmann, S., Vitale, C., Schmidt, H., Drexel, H., Patak, A., Torp-Pedersen, C., Kjeldsen, K. P., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv161 · Cited by 175
Self-citationGender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers
LUZIER, A., KILLIAN, A., WILTON, J., WILSON, M., FORREST, A., & KAZIERAD, D. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)90068-1 · Cited by 175
Gender differences in drug toxicity
Nicolson, T. J., Mellor, H. R., & Roberts, R. R. A. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.12.001 · Cited by 175
Mancini, G. B. J., Tashakkor, A. Y., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D. S., et al. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.09.023 · Cited by 173
Status of Women in Cardiovascular Clinical Trials
Kim, E. S. H., & Menon, V. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.179796 · Cited by 171
Influence of Menstrual Cycle on QT Interval Dynamics
NAKAGAWA, M., OOIE, T., TAKAHASHI, N., TANIGUCHI, Y., ANAN, F., YONEMOCHI, H., & SAIKAWA, T. (2006) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2006.00407.x · Cited by 171
Huxley, V. H. (2007) · Advances in Physiology Education · doi:10.1152/advan.00099.2006 · Cited by 171
Kotecha, D., Manzano, L., Krum, H., Rosano, G. M. C., Holmes, J., Altman, D. G., Collins, P., Packer, M., Wikstrand, J., Coats, A. J. S., et al. (2016) · BMJ · doi:10.1136/bmj.i1855 · Cited by 171
Self-citationKashuba, A. D. M., & Nafziger, A. N. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199834030-00003 · Cited by 167
White, H. D., Barbash, G. I., Modan, M., Simes, J., Diaz, R., Hampton, J. R., Heikkilä, J., Kristinsson, A., Moulopoulos, S., & Paolasso, E. A. (1993) · Circulation · doi:10.1161/01.cir.88.5.2097 · Cited by 167
Cummins, C. L., Wu, C., & Benet, L. Z. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128388 · Cited by 166
Becker, R. C., Spencer, F. A., Gibson, M., Rush, J. E., Sanderink, G., Murphy, S. A., Ball, S. P., & Antman, E. M. (2002) · American Heart Journal · doi:10.1067/mhj.2002.120774 · Cited by 166
Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers
Hagg, S., Spigset, O., & Dahlqvist, R. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01328.x · Cited by 164
Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., et al. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1039980 · Cited by 162
Gender and Acute Myocardial Infarction: Is There a Different Response to Thrombolysis?
Woodfield, S. L., Lundergan, C. F., Reiner, J. S., Thompson, M. A., Rohrbeck, S. C., Deychak, Y., Smith, J. O., Burton, J. R., McCarthy, W. F., Califf, R. M., et al. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00449-4 · Cited by 160
Legnani, C., Noventa, F., Palareti, G., Pengo, V., & ISCOAT, T. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615599 · Cited by 157
Gender Differences in Platelet GPIIb-IIIa Activation
Faraday, N. R., Goldschmidt‐Clermont, P. J., & Bray, P. F. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656045 · Cited by 152
Pratt, C. M., Camm, A. J., Cooper, W., Friedman, P. L., MacNeil, D. J., Moulton, K. M., Pitt, B., Schwartz, P. J., Veltri, E. P., & Waldo, A. L. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00006-x · Cited by 151
Becker, R. C., Hochman, J. S., Cannon, C. P., Spencer, F. A., Ball, S. P., Rizzo, M. J., & Antman, E. M. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00582-8 · Cited by 148
de Werf, F. V. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2686 · Cited by 147
The Relative Efficacy and Safety of Clopidogrel in Women and Men
Berger, J. S., Bhatt, D. L., Cannon, C. P., Chen, Z., Jiang, L., Jones, J. B., Mehta, S. R., Sabatine, M. S., Steinhubl, S. R., Topol, E. J., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.074 · Cited by 145
Sex- and age-related antihypertensive effects of amlodipine
Kloner, R. A., Sowers, J. R., DiBona, G. F., Gaffney, M., & Wein, M. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89205-3 · Cited by 141
Kim, E., Carrigan, T., & Menon, V. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.025 · Cited by 139
Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)
Gaudet, D., Watts, G. F., Robinson, J. G., Minini, P., Sasiela, W. J., Edelberg, J. M., Louie, M. J., & Raal, F. J. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.09.010 · Cited by 139
Women's Health Research: Progress, Pitfalls, and Promise
Taylor, J. S. (2011) · Health Care For Women International · doi:10.1080/07399332.2011.562837 · Cited by 133
Gender as a Risk Factor for Adverse Events to Medications
Kando, J. C., Yonkers, K. A., & Cole, J. O. (1995) · Drugs · doi:10.2165/00003495-199550010-00001 · Cited by 128
Mikkola, T. S., Turunen, P., Avela, K., Orpana, A., Viinikka, L. U., & Ylikorkala, O. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.6.7775630 · Cited by 128
Risk factors for statin‐associated rhabdomyolysis
Schech, S. D., Graham, D. J., Staffa, J. A., Andrade, S. E., Grenade, L. L., Burgess, M., Blough, D. K., Stergachis, A. S., Chan, K. A., Platt, R. G., et al. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1287 · Cited by 128
Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects
Walle, T., Walle, U. K., Cowart, T. D., & Conradi, E. C. (1989) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1989.136 · Cited by 126
Heparin kinetics: Variables related to disposition and dosage
Cipolle, R. J., Seifert, R. D., Neilan, B. A., Zaske, D. E., & Haus, E. (1981) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1981.53 · Cited by 126
Clopidogrel response variability: Current status and future directions
Ferreiro, J. L., & Angiolillo, D. J. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0185 · Cited by 121
Kubitza, D., Becka, M., Roth, A., & Mueck, W. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.5 · Cited by 116
Cited by
Sex differences in pharmacokinetics predict adverse drug reactions in women
Zucker, I., & Prendergast, B. J. (2020) · Biology of Sex Differences · doi:10.1186/s13293-020-00308-5 · Cited by 777
Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes
Regitz-Zagrosek, V., & Gebhard, C. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00797-4 · Cited by 386
Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants
Millett, E. R. C., Peters, S. A. E., & Woodward, M. (2018) · BMJ · doi:10.1136/bmj.k4247 · Cited by 364
Vinarov, Z., Abdallah, M., Agundez, J. A. G., Allegaert, K., Basit, A. W., Braeckmans, M., Ceulemans, J., Corsetti, M., Griffin, B. T., Grimm, M., et al. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105812 · Cited by 359
Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review
Stillhart, C., Vučićević, K., Augustijns, P., Basit, A. W., Batchelor, H., Flanagan, T. R., Gesquiere, I., Greupink, R., Keszthelyi, D., Koskinen, M., et al. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105280 · Cited by 320
Metadata
- Authors
- Tamargo, J., Rosano, G., Walther, T., Duarte, J., Niessner, A., Kaski, J., Ceconi, C., Drexel, H., Kjeldsen, K., Savarese, G., Torp-Pedersen, C., Atar, D., Lewis, B., & Agewall, S.
- Venue
- European Heart Journal - Cardiovascular Pharmacotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-02-28
- Volume
- 3
- Issue
- 3
- Pages
- 163-182
- ISSN
- 2055-6837 (ISSN-L)
- 2055-6845
- OpenAlex
- W2592398938
- Cited by
- 317
- References
- 290
- FWCI
- 13.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.